Golotta (AbbVie): "Siamo molto impegnati in ricerca cure per malattie reumatologiche e non solo. In sviluppo Jak inibitore per Les"

adnkronos

(Adnkronos) - ‘Già autorizzato in altre patologie autoimmuni upadacitinib è in sperimentazione clinica per il Lupus eritematoso sistemico’.

Transcript

00:00Improving the standards of care and clinical results for patients suffering from rheumatological diseases and not only.

00:11With these goals, AVI has focused attention on its inhibitor, Upadacitinib.

00:17This oral therapy, authorized for other autoimmune diseases, is already available in Italy

00:22and is also being studied for the treatment of a complex disease such as lupus erythematosus systemic.

00:27But where does the commitment of this pharmaceutical company for lupus erythematosus come from?

00:31We asked Caterina Golotta, Director of AVI Italy.

00:35AVI is an ultraventricular experience in rheumatology

00:38and brings in this therapeutic area the approach of improving the standards of care

00:44and improving the results for patients suffering from rheumatological diseases.

00:51Specifically, lupus erythematosus systemic, or LES, is an extremely complex autoimmune disease

00:58characterized by the production of autoantibodies

01:02that can hit various organs and systems in a varied and heterogeneous way.

01:08The pulmonary system, the skeletal muscle system, the cuticle and the central nervous system.

01:14Clearly, the symptoms vary depending on the type of narrow organ involved.

01:20Lupus erythematosus has an extremely unpredictable chronic course.

01:23That is why the unsatisfied need is very strong

01:28and AVI is committed to developing a possible further tool for doctors

01:35to respond to the needs of patients suffering from this pathology.

01:40Specifically, our inhibitor of JAK, lupatacitinib,

01:45is currently undergoing clinical experimentation in this context.

01:49And what is this therapy specifically about?

01:51On which pathologies has it shown to act positively?

01:54Lupatacitinib is our inhibitor of JAK

01:57and is the result of the effort, research and internal development of AVI.

02:00It is an irreversible selective inhibitor of JAK-Inasi

02:04and is currently approved and reimbursed in a series of immunological pathologies.

02:10Arthritis rheumatoide, spondylitis architosanthe,

02:13psoriasis arthritis, colitis ulcerosa and atopic dermatitis.

02:18We remain confident of the results of the molecule

02:22in the development program of lupus erythematosus.

02:26Among other things, lupatacitinib is currently being studied

02:30in two other pathologies of the immunological field,

02:33vitiligin and alopecia areata.

02:36But what does AVI do?

02:39AVI is a global biopharmaceutical company

02:42based on research, focused on patients

02:45and specifically on innovation and research and development,

02:48with the aim of having a significant impact on the lives of patients

02:53and focusing on therapeutic areas of which it has great experience.

02:57Immunology, oncology, virology, neurosciences,

03:01ophthalmology and aesthetic medicine.

03:04We are present in the world in more than 70 countries

03:07with about 47,000 employees.

03:10In general, AVI's research commitment in 2024

03:13was equal to about 13 billion dollars,

03:16which represents an increase of 66.66%

03:20compared to the commitment of 2023.

03:23In our country, this company is carrying out

03:2678 clinical studies involving about 400 experimental centers.

03:30In Italy, the history of AVI is long.

03:33We have been present since 1949 with Abbott.

03:36AVI was born in 2013 as a spin-off of Abbott

03:41and today has about 1,700 employees in Italy.

03:45Half of these employees work in the Campoverde production pole,

03:49which represents a flagship for us.

03:52The company has invested a lot in the Campoverde pole

03:56to bring it to very high standards of competitiveness

03:59and environmental sustainability.

04:02These standards have allowed us to bring to our country

04:05the production of many active-principle drugs

04:08that make them available in the world.

Category

Transcript

Recommended